A type of targeted therapy that consists of an antibody linked to a payload drug. The drug is often cytotoxic. In an oncology setting, the antibody binds to a target cancer cell, and the payload drug is released within the cell .
Glossary
Antibody-Drug Conjugates (ADCs)
03.19.13
-
Breaking News | Drug Development | Industry News | Preclinical Outsourcing
Pierre Fabre Buys Igenica Immuno-oncology Assets
Deal reinforces Pierre Fabre’s pipeline in oncology, its primary R&D focus area
-
Breaking News | Collaborations & Alliances | Drug Development | Industry News | Preclinical Outsourcing | R&D
Nektar and Takeda in Research Collaboration
Will explore combination cancer therapies
-
Bio News | Breaking News | Clinical Trials | Collaborations & Alliances | Industry News
Merck Teams With Aduro Biotech on Cancer Drug Trial
Will evaluate the combination of Aduro’s CRS-207 with Merck’s Keytruda
-
Collaborations & Alliances | Drug Development
BMS, Calithera Biosciences Expand Clinical Collaboration
Will evaluate Opdivo in combination with CB-839 in NSCLC and Melanoma
-
Breaking News | cGMP Manufacture | Formulation Development | Industry News | Solid Dosage/Creams/Ointments
Catalent Manufactures Lexicon’s Xermelo Following Approval
To provide commercial supply of first-in-class oral therapy from its Kansas City facility
